Eli Lilly

Researcher handling clinical vials and a precision pipette during peptide testing.

October 6, 2026

28.3% Weight Loss, 65% Below BMI 30: Eli Lilly’s Retatrutide Phase 3 Data Just Reset the Bar for Obesity Drugs

A Phase 3 clinical trial of Eli Lilly’s investigational obesity drug retatrutide produced weight loss results that exceed anything a currently approved medicine has achieved. At the highest dose tested over 80

High-magnification scanning electron micrograph displaying the outer surface and irregular membrane of a human breast cancer cell.

Health·News·Science

FDA Approves Lilly’s Inluriyo and Verzenio Combination for ESR1-Mutated Breast Cancer

Oncology FDA Approves Lilly’s Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer The all-oral combination doubled median progression-free survival in a key trial subgroup. Here’s how it works, who it’s for, and what side effects to know. 📅 September 18, 2026

September 19, 2026

Eli Lilly’s Mounjaro Wins FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes

Health·USA

The Food and Drug Administration approved Lilly’s Mounjaro on Friday to reduce the risk of cardiovascular death, heart attack, and stroke in adults with

Medicare Opens GLP-1 Obesity Coverage at $50 a Month Under the CMS BALANCE Model

Business·Health·Policy

CMS is extending GLP-1 coverage to Medicare and Medicaid beneficiaries with obesity at a $50 monthly copay through the BALANCE model and Medicare GLP-1

Donald J. Trump in a navy suit and bright blue tie pumps his fist while walking on an airport tarmac.

Health·Policy

GLP-1 Drug Prices Cut: Wegovy $149, Zepbound $299 on TrumpRx — “Promise Made. Promise Kept.”

On November 6, 2025, President Donald Trump announced agreements with pharmaceutical companies Eli Lilly and Novo Nordisk to reduce prices for GLP-1 obesity medications. The announcement took place in the Oval Office

Tejal Somvanshi

November 9, 2025